Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Ihle

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathwayGarth Powis, Nathan Ihle, D Lynn Kirkpatrick
AAPS Pharmscitech|January 6, 2018
Control Strategy for Small Molecule Impurities in Antibody-Drug ConjugatesHai H Gong, Nathan Ihle, Michael T Jones, et al.
Oncology Research|November 24, 2004
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316Emmanuelle J Meuillet, Nathan Ihle, Amanda F Baker, et al.
Cancer Research|June 4, 2009
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKTSylvestor A Moses, M Ahad Ali, Song Zuohe, et al.
Journal of Pharmaceutical Sciences|September 23, 2023
CMC Regulatory Considerations for Antibody-Drug ConjugatesKaroline Bechtold-Peters, Andrea Ruggiero, Nienke Vriezen, et al.
Molecular Cancer Therapeutics|September 16, 2008
Discovery of a novel class of AKT pleckstrin homology domain inhibitorsDaruka Mahadevan, Garth Powis, Eugene A Mash, et al.
Molecular Cancer Therapeutics|March 4, 2010
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitorEmmanuelle J Meuillet, Song Zuohe, Robert Lemos, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathwayGarth Powis, Nathan Ihle, D Lynn Kirkpatrick
AAPS Pharmscitech|January 6, 2018
Control Strategy for Small Molecule Impurities in Antibody-Drug ConjugatesHai H Gong, Nathan Ihle, Michael T Jones, et al.
Oncology Research|November 24, 2004
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316Emmanuelle J Meuillet, Nathan Ihle, Amanda F Baker, et al.
Cancer Research|June 4, 2009
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKTSylvestor A Moses, M Ahad Ali, Song Zuohe, et al.
Journal of Pharmaceutical Sciences|September 23, 2023
CMC Regulatory Considerations for Antibody-Drug ConjugatesKaroline Bechtold-Peters, Andrea Ruggiero, Nienke Vriezen, et al.
Molecular Cancer Therapeutics|September 16, 2008
Discovery of a novel class of AKT pleckstrin homology domain inhibitorsDaruka Mahadevan, Garth Powis, Eugene A Mash, et al.
Molecular Cancer Therapeutics|March 4, 2010
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitorEmmanuelle J Meuillet, Song Zuohe, Robert Lemos, et al.
Pageof 1